Flexion Therapeutics Announces That FDA Has Removed

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Flexion Therapeutics Announces That FDA Has Removed Clinical Hold on FX006

- Company Resumes Recruitment in Pivotal Phase 2b Trial; I nitiation of Phase 3 Clinical Trial Planned for Early 2015
- Conference Call Scheduled for Tomorrow, December 2, 2014 at 9:00 a.m. ET

BURLINGTON, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that it has lifted the clinical hold on Flexion's lead drug candidate FX006, based upon the company successfully completing the FDA's requested testing and investigation related to what was originally reported as a single case of septic arthritis of the knee. As a result, Flexion intends to immediately resume recruitment and dosing in its pivotal Phase 2b trial of FX006, and to initiate a planned Phase 3 trial in early 2015. FX006 is a first-in-class injectable, sustained-release, intra-articular steroid treatment in development for patients with moderate to severe osteoarthritis (OA) pain.

Michael Clayman, M.D., Flexion Therapeutics President and CEO, said, "We are pleased to have been able to rapidly provide data to the FDA that allowed the agency to remove the clinical hold. Now we can continue to advance FX006, which has the potential to make a real difference for the many individuals who suffer from OA pain."

On September 16, 2014, the FDA placed a clinical hold on FX006 due to a single occurrence of what was then described as an infection in the injected knee joint of a patient in the pivotal Phase 2b trial. The subsequent clinical hold letter from the FDA requested that the company:

  • Determine whether the study drug was the source of infection by recovering both the specific study drug vials used in the treatment of the patient who experienced the infection, as well as unused study drug vials from the clinical site where the patient was injected and test them for contamination, and
  • Explore other potential causes for infection, including a compromise of sterile procedures during injection.

In accordance with these FDA requests, the company performed industry standard contamination tests through a certified third-party sterility-testing firm, which demonstrated that no microbial growth could be detected in any of the used or unused vials. As a result, the company concluded that study drug was not contaminated. The company also explored other potential causes of possible infection including contamination during the preparation or administration of FX006. Following consultations with the principal investigator, the study coordinator that prepared the study drug, and the healthcare professional that administered the injection at the clinical site, the company could not find any indication that sterile procedures were compromised during the injection. There have been no other infections noted in the approximately 100 other patients dosed with FX006 in this trial.

On October 28, 2014, the company received notification that based on the highly atypical nature of this patient's presentation as it relates to septic arthritis and the subsequent clinical course, which was most consistent with rheumatoid arthritis, the principal investigator has changed the initial serious adverse event diagnosis from septic arthritis, possibly related to study drug treatment, to inflammatory arthritis, unrelated to study drug treatment. The original, and only, positive synovial fluid culture obtained from this patient is presumed to be a false positive, which occurs in about five percent of such cases. Thus there have been no confirmed diagnoses of septic arthritis among the more than 300 patients treated with FX006 in all clinical trials to date and no serious adverse events that have been attributed to study drug.

About Flexion Therapeutics

Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead program, FX006, is an intra-articular sustained release steroid in development for patients with moderate to severe OA pain. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.

Conference Call

Flexion's management team will host a conference call and webcast at 9:00 a.m. EST tomorrow, December 2, 2014, to discuss the removal of the clinical hold and to provide a clinical timing update. The dial-in number for the conference call is toll-free (855) 770-0022 for domestic participants and (908) 982-4677 for international participants. A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website at www.flexiontherapeutics.com . A webcast replay will be available online after the call.

Forward-Looking Statements

Statements in this press release regarding matters that are not historical facts, including statements relating to the future of Flexion, its ongoing development of its product candidates, expectations of resuming the FX006 Phase 2b clinical trial, plans and timing for initiating a Phase 3 trial, anticipated clinical and other milestones (including the timing of such milestones) and potential benefits of FX006 are forward-looking statements. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks associated with the process of discovering, developing and obtaining regulatory approval for drugs that are safe and effective for use as human therapeutics, the fact that Flexion relies on third parties to manufacture and conduct the clinical trials of its product candidates, which could delay or limit their future development or regulatory approval, the fact that Flexion will require additional capital, including prior to completing Phase 3 development of, filing for regulatory approval for, or commercializing, FX006 or any of its other product candidates and may be unable to obtain such additional capital in sufficient amounts or on terms acceptable to it, and other risks and uncertainties described in Flexion's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Flexion's Annual Report on Form 10-K for the year ended December 31, 2013 and subsequent filings with the SEC. You are encouraged to read Flexion's filings with the SEC, available at www.sec.gov , for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and Flexion undertakes no obligation to update or revise any of the statements.

Media Contact Jamie Lacey-Moreira PressComm PR, LLC T: 410-299-3310 Corporate Contact Lisa Davidson, MBA Vice President, Finance and Administration Flexion Therapeutics, Inc. T: 781-305-7765

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 173

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 50

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 74

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 21

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 43

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 229

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 44

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 35

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 102

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Crypto Volatility and the REX Osprey XRP ETF

Updated Category News Views 134

Cryptocurrency Market Overview and Recent Trends Up until October, the cryptocurrency market was experiencing significant growth, with a total capitalization reaching approximately $4.28 trillion. This surge was driven by abundant liquidity and a heightened risk appetite among investors. However, the capital markets can be unpredictable, leading to a swift and adverse...

Continue Reading
Intelligent Bio Inks Global Deal to Expand Drug Testing Solutions

Updated Category News Views 126

Intelligent Bio Solutions Launches Global Distribution Pact Intelligent Bio Solutions Inc. (NASDAQ: INBS) has recently announced an exciting global distribution partnership with SMARTOX. This collaboration aims to introduce their innovative SmarTest Patch, a cutting-edge product designed for drug detection, to international markets beyond the U.S. and Canada, marking a...

Continue Reading
Discover the Long-Term Growth of American Financial Group AFG Stock

Updated Category News Views 148

The Remarkable Journey of American Financial Group (AFG) American Financial Group (AFG) has significantly outperformed the market over the past twenty years, showing an annualized return of 9.37%, which surpasses the market by 1.29%. With a market capitalization standing at an impressive $10.39 billion, AFG is a noteworthy player in the financial sector. Investment...

Continue Reading
Current Sentiment Analysis: Canaan Inc's Short Interest Insights

Updated Category News Views 352

Canaan Inc's Current Short Interest Overview Canaan Inc (NYSE: CAN) is witnessing changes in its stock sentiment, particularly regarding its short interest. Recent reports indicate that the short interest, expressed as a percentage of the float, has dropped by 8.14%. Currently, 36.17 million shares are sold short, representing 8.58% of the total shares available for...

Continue Reading
CalExitNow Push for CA GOP Ban & Sovereignty Talks

Updated Category News Views 296

California's Political Pot Stirs In the wild world of politics, California stands as a fiery beacon yet again. This time, CalExitNow, a fiery group championing California's self-determination, is taking aim at the state’s Republican Party. Reminds me of a stock under pressure—hesitate at your peril as the winds of change sweep through. Disqualification Petition: A...

Continue Reading